- /
- Supported exchanges
- / US
- / NERV.NASDAQ
Minerva Neurosciences Inc (NERV NASDAQ) stock market data APIs
Minerva Neurosciences Inc Financial Data Overview
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Minerva Neurosciences Inc (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Minerva Neurosciences Inc data using free add-ons & libraries
Get Minerva Neurosciences Inc Fundamental Data
Minerva Neurosciences Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -15 097 528
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
Get Minerva Neurosciences Inc Earnings data
Corporate Events Calendar & News package for
What’s included:
- Latest Release: 2026-05-12
- EPS/Forecast: -0.138
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Minerva Neurosciences Inc News
New
Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum
BURLINGTON, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ...
Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum
Minerva Neurosciences, Inc BURLINGTON, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of t...
Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company’s Board of Directors
BURLINGTON, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central n...
Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates
BURLINGTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central n...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.